Muir J W, Besser G M, Edwards C R, Rees L H, Cattell W R, Ackrill P, Baker L R
Clin Nephrol. 1983 Dec;20(6):308-14.
Twenty-five men on maintenance hemodialysis commenced a placebo-controlled, double-blind, crossover trial of bromocriptine for erectile impotence. Eight patients on bromocriptine and one on placebo failed to complete the trial due to side-effects and 2 were withdrawn following renal transplantation. Libido or the frequency and/or quality of erections or both improved in 11 of the remaining 14 patients during bromocriptine treatment. A significant (P less than 0.01) improvement in patients' perception of sexual performance occurred on bromocriptine compared with placebo. The 3 patients in whom potency failed to improve had the lowest serum testosterone concentrations. Bromocriptine is usually effective in the management of impotence in males receiving maintenance hemodialysis provided pretreatment serum testosterone is above the lower end of the normal range, but side-effects are relatively common.
25名维持性血液透析男性患者开始了一项关于溴隐亭治疗勃起功能障碍的安慰剂对照、双盲、交叉试验。8名服用溴隐亭的患者和1名服用安慰剂的患者因副作用未能完成试验,另有2名患者在肾移植后退出试验。在其余14名患者中,11名在接受溴隐亭治疗期间性欲或勃起频率和/或质量或两者均有所改善。与安慰剂相比,服用溴隐亭的患者对性功能的感知有显著(P<0.01)改善。3名性功能未改善的患者血清睾酮浓度最低。如果治疗前血清睾酮高于正常范围下限,溴隐亭通常对接受维持性血液透析的男性阳痿有效,但副作用相对常见。